FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pulmonology, cardiology and respiratory sleep medicine. LVDD is diagnosed in patient with apnea-hypopnea by questioning patients and night printing. Indices of apnea-hypopnea index are specified, according to Epworth sleepiness scale, minimum night saturation and saturation time less than 90%. Then, using the formula given by us: z=20.55237+(-0.043966)×(A)+0.7923×(E)+(-0.43599)×(S)+0.080403×(T), where "A" is an apnea-hypopnea index (events per hour), "E" is a number of Epworth sleepiness scores, "S" is minimum night saturation (%), "T" is saturation time less than 90% (% of total sleep time), calculating sum (z) of numerical values of features multiplied by discriminant coefficient of feature (-0.043966 for index of apnea-hypopnea, 0.7923 for number of points on scale of Epworth sleepiness, (-0.43599) for minimum night saturation, 0.080403 for saturation time less than 90%), and summed with constant equal to 20.55237. Considering logistic function of type
it is possible to calculate LVDD probability in patient with apnea-hypopnea by known formula (source: Hosmer David W., Stanley Lemeshow (2000). Applied Logistic Repression. 2nd ed New York; Chichester, Wiley. ISBN 0-471-35632-8)
where e is the base of the natural logarithm = 2.71828947 ..., z is the sum of the numerical values of each of the features. Thus, LVDD is obtained in the patient with apnea-hypopnea by the value of which the risk of cardiovascular complications is predicted. If probability is 50% or more, the LVDD risk in the apnea-hypopnea patient is predicted, followed by developing cardiovascular complications; if the probability is less than 50%, the LVDD risk in the apnea hypopnea patient is low.
EFFECT: invention provides a method for determining the probability of left ventricular diastolic dysfunction (LVDD) in a patient with apnea-hypopnea by a limited number of clinical signs, having separate and combined high sensitivity and specificity.
1 cl, 2 tbl, 1 dwg
